Clinical Trial

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a phase l multi-centric, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. In total approximately 48 patients will be included in the trial. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06 -> 2026-09 2026-07-25
minor Completion pushed: 2026-06 -> 2026-09 2026-07-25
Trial Details
NCT Number NCT03853616
Lead Sponsor Miltenyi Biomedicine GmbH
Conditions Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, Chronic Lymphocytic Leukemia Recurrent, Chronic Lymphocytic Leukemia Refractory
Enrollment 48 participants
Start Date 2018-11-26
Primary Completion 2026-09 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-24